Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies

Arnaud Del Bello, Martine Neau‐Cransac, Laurence Lavayssiere, Valérie Dubois, Nicolas Congy‐Jolivet, Jonathan Visentin, Marie Danjoux, Brigitte Le Bail, Valérie Hervieu, Olivier Boillot, Teresa Antonini, Nassim Kamar, Jérôme Dumortier – 14 October 2019 – After liver transplantation (LT), the role of preformed donor‐specific anti–human leukocyte antigen antibodies (pDSAs) remains incompletely understood. We conducted a retrospective, case‐control analysis to determine the impact of pDSAs after LT in 3 French transplant centers (Bordeaux, Lyon, and Toulouse).

Subscribe to